abstract |
Liquid composition comprising 0.01 to 1.5 mg / ml, preferably 0.01 to 0.5 mg / ml, of GLP-1 agonists and / or a pharmacologically tolerable salt thereof, 240-3000 nmol / ml of insulin and / or a pharmacologically tolerable salt thereof and, eventually, at least one pharmaceutically acceptable adjuvant, characterized in that it contains 0.5-20 mg / ml of methionine. |